EXTON, Pa., May 6 /PRNewswire/ -- BioTrends is pleased to announce the publication of a new syndicated report, TreatmentTrends®: Rheumatoid Arthritis. This report covers the use of biologics for the ...
The authors' preferred hypothesis to explain the rapid clinical improvement observed centers on the emerging evidence, which suggests that TNF-alpha is of critical importance in the regulation of ...
Tumor necrosis factor (TNF)–alpha inhibitors achieve better endoscopic healing than the newer biologic drugs vedolizumab (Entyvio) and ustekinumab (Stelara) in moderate to severe Crohn's disease, a ...
Scientists have made more progress in understanding the process behind scar-tissue formation and wound healing – specifically, a breakthrough in fibroblast-to-fibrocyte signaling involving two key ...
Positive clinical data validates current Phase 2b clinical trial of isomyosamine as a treatment for chronic inflammation associated with muscle loss BALTIMORE--(BUSINESS WIRE)--TNF Pharmaceuticals, ...
BALTIMORE--(BUSINESS WIRE)--TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) (“TNF” or the “Company”), a clinical stage biopharmaceutical company committed to developing novel therapies for autoimmune and ...
Tumor necrosis factor (TNF) inhibitors for rheumatoid arthritis were linked with a lower risk of Alzheimer's disease and related dementia, but only in people with cardiovascular disease, data from the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback